Dudediligence.

X4 Pharmaceuticals, Inc

XFORNASDAQ · Biological Products, (No Diagnostic Substances)
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$434,494

4 notices · 100,740 sh

Dec 2025 to Oct 2026

Reported ·

$72,763

1 sale · 1 buy · $249,997 bought

Oct 2025 to Jun 2026

The two figures cover different periods.

The one reported sale does not carry the 10b5-1 box. It is 0.02% of the shares on issue.

PLANNED · FORM 144Dec 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-10-01: David Kirske, Form 1442026-08-12: John Volpone, Form 1442026-08-12: Adam Craig, Form 1442026-05-12: David Kirske, Form 1442025-10-23: Craig Adam R, bought2026-05-12: KIRSKE DAVID, sold
under a no plan named▼ sale▲ buysize is dollars

Form 144 notices, newest first

2026-10-01David Kirske, Chief Financial Officer$33,658
11,767 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-12John Volpone, President$111,944
24,576 shno plan dateForm 4s on file end Jun 23144 ↗
2026-08-12Adam Craig, Executive Chairman$216,071
47,436 shno plan dateForm 4s on file end Jun 23144 ↗
2026-05-12David Kirske, Chief Financial Officer$72,820
16,961 shno plan date144 ↗
Form 4, 2026-05-13: sold 16,961 at $4.29 Form 4 ↗